STATUS OF PD-1 AND PD-L1 EXPRESSION IN INVASIVE UROTHELIAL CARCINOMA OF THE BLADDER WITH MISMATCH REPAIR PROTEIN DEFICIENCY

被引:0
|
作者
Sungu, Nuran [1 ,2 ,3 ]
Kiran, Merve M. [2 ]
机构
[1] Ankara Yildirim Beyazit Univ, Fac Med, Dept Pathol, Ankara, Turkiye
[2] Ankara City Hosp, Dept Pathol, Ankara, Turkiye
[3] Ankara Yildirim Beyazit Univ, Fac Med, Dept Pathol, Univ Dist 1604 St 9, Cankaya Ankara, Turkiye
关键词
bladder; urothelial cancer; PD-1; PD-L1; MSI; LYNCH SYNDROME; MICROSATELLITE INSTABILITY; IMMUNE ESCAPE; CANCER; CARRIERS; TUMORS; MSH2;
D O I
10.5114/PJP.2023.132221
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
It has been reported that mismatch repair deficient (d-MMR) tumors show sen-sitivity to immune checkpoint inhibitors. We aimed to evaluate the correla-tion of d-MMR and PD-1/PD-L1 expression in invasive urothelial carcinoma of the bladder. Tissue microarray (TMA) tissues were stained PD-1/PD-L1 and MMR proteins. The expression ratio of these markers has been compared with histopathologic parameters. d-MMR tumors were more superficial muscle invasive (p = 0.012). When the d-MMR, and PD-1/PD-L1 expression ratios were examined, a significant correlation was obtained between the d-MMR and PD-L1 expression ratio of > 5% in both the tumor and immune cells (p = 0.02 and p = 0.004, respectively). The expression ratio was higher in the patients without MMR loss. PD-1 and PD-L1expression in those with MSH6 loss was one or none. When PD1/PDL1 expression was compared with histopathological parameters, a significant relationship was observed between tumor grade and depth of muscle invasion. PD-L1 expression was not observed in the superficial muscle invasive tumors. This study was shown the status of d-MMR and PD-1/PD-L1 in invasive urothelial cancers and their correlation with prognostic markers. PD-1/PD-L1 ex -pression may contribute to the progression and poor prognosis of bladder cancer. However, further studies are required to research the clinical utility.
引用
收藏
页码:161 / 170
页数:10
相关论文
共 50 条
  • [1] Mismatch repair protein and PD-1/PD-L1 expression in pancreatic neuroendocrine neoplasm
    Duan, X. L.
    Hao, S. M.
    Zhao, M.
    Mi, L.
    Shi, J.
    Li, N.
    Yin, X. L.
    Han, X.
    Han, G. J.
    Wang, J. F.
    Li, C. Z.
    Yin, F.
    JOURNAL OF NEUROENDOCRINOLOGY, 2021, 33 : 106 - 106
  • [2] PD-L1 Protein Expression and PD-L1 Gene Amplification in Urothelial Carcinoma of the Urinary Bladder
    Zuo, Chunlai
    Kallakury, Bhaskar V. S.
    Firestone, Bryan
    Voronel, Olga
    Sheehan, Christine E.
    Nazeer, Tipu
    Ross, Jeffrey S.
    MODERN PATHOLOGY, 2016, 29 : 272A - 272A
  • [3] PD-L1 Protein Expression and PD-L1 Gene Amplification in Urothelial Carcinoma of the Urinary Bladder
    Zuo, Chunlai
    Kallakury, Bhaskar V. S.
    Firestone, Bryan
    Voronel, Olga
    Sheehan, Christine E.
    Nazeer, Tipu
    Ross, Jeffrey S.
    LABORATORY INVESTIGATION, 2016, 96 : 272A - 272A
  • [4] Correlation of mismatch repair deficiency with expression of PD-L1 and CD8 in high grade urothelial carcinoma of bladder
    Downes, M.
    Hodgson, A.
    Xu, B.
    VIRCHOWS ARCHIV, 2019, 475 : S4 - S4
  • [5] Correlation of mismatch repair protein deficiency, PD-L1 and CD8 expression in high-grade urothelial carcinoma of the bladder
    Hodgson, Anjelica
    Vesprini, Danny
    Liu, Stanley K.
    Xu, Bin
    Downes, Michelle R.
    JOURNAL OF CLINICAL PATHOLOGY, 2020, 73 (08) : 519 - 522
  • [6] Mismatch repair status and high expression of PD-L1 in nasopharyngeal carcinoma
    Zhao, Liang
    Liao, Xiyi
    Hong, Ganji
    Zhuang, Yanzhen
    Fu, Kaili
    Chen, Peiqiong
    Wang, Yuhuan
    Chen, Haojun
    Lin, Qin
    CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 1631 - 1640
  • [7] Evaluation of PD-1 and PD-L1 expression in canine urothelial carcinoma cell lines
    Pinard, Christopher J.
    Hocker, Samuel E.
    Poon, Andrew C.
    Inkol, Jordon M.
    Matsuyama, Arata
    Wood, R. Darren
    Wood, Geoffrey A.
    Woods, J. Paul
    Mutsaers, Anthony J.
    VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY, 2022, 243
  • [8] Prognostic value of PD-1/PD-L1 expression in upper tract urothelial carcinoma
    Campedel, L.
    Seisen, T.
    Cussenot, O.
    Comperat, E.
    Varinot, J.
    Roupret, M.
    Cancel-Tassin, G.
    PROGRES EN UROLOGIE, 2018, 28 (16): : 900 - 905
  • [9] The Relationship Between Mismatch Repair Deficiency and PD-L1 Expression in Breast Carcinoma
    Mills, Anne M.
    Dill, Erik A.
    Moskaluk, Christopher A.
    Dziegielewski, Jaroslaw
    Bullock, Tim N.
    Dillon, Patrick M.
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2018, 42 (02) : 183 - 191
  • [10] PD-1 and PD-L1 Inhibitors as Salvage Therapy for Urothelial Carcinoma
    Sonpavde, Guru
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (11): : 1073 - 1074